Preview

Cardiovascular Therapy and Prevention

Advanced search

Metformin in metabolic syndrome treatment

Abstract

Aim. To compare the influence of standard and complex (including metformin) antihypertensive therapy on 24- hour blood pressure monitoring (BPM), biochemical and hormonal parameters in patients with metabolic syndrome (MS).
Material and Methods. The study included 54 patients with MS: 34 males and 20 females aged 30-61, without manifested Type 2 diabetes mellitus (DM). Group A (28 MS patients) received antihypertensive drugs only – verapamil, if necessary combined with ACE inhibitors and diuretics. Group B (25 MS patients) was additionally administered metformin. At baseline and after 8-week therapy, 24-hour BPM was performed; basal levels of insulin, C-reactive protein (CRP), cholesterol, triglycerides (TG), high-density lipoproteins (HDL), and uric acid were measured.
Results. In Group A, there was no significant dynamics in lipid and carbohydrate metabolism parameters. In Group B, basal levels of CRP (p<0.05), TG (p<0.1) had decreased, and HDL concentration has increased (p<0.01).
Conclusion. In MS patients without DM, adding minimal therapeutic doses of metformin to standard antihypertensive treatment significantly improved lipid and carbohydrate metabolism parameters.

About the Authors

V. I. Podzolkov
I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation


D. A. Napalkov
I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation


V. I. Makolkin
I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation


References

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-600.

2. Зимин Ю.В. Происхождение, диагностическая концепция и клиническое значение синдрома инсулинорезистентности или метаболического синдрома X. Кардиология 1998; 6: 71-81.

3. Чазова И.Е., Мычка В.Б. Метаболический синдром и артериальная гипертония. Артер гиперт 2002; 8(1): 9-13.

4. Преображенский Д.В., Сидоренко Б.А. Артериальная гипертензия при сахарном диабете. РМЖ 1999; 7(7): 340-4.

5. Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика и подходы к лечению. РМЖ 2001; 9(2): 56-60.

6. Маколкин В.И., Подзолков В.И., Напалков Д.А. Метаболический синдром с точки зрения кардиолога: диагностика, немедикаментозные и медикаментозные методы лечения. Кардиология 2002; 12: 91-7.

7. Standarts of Medical Care for Patients with Diabetes Mellitus. Diabetes Care 1998; 21(Suppl 1): 3-14.

8. Nilsson P, Lind L, Anderson P, et al. On the use of ambulatory blood pressure recordings and insulin sensitivity measurements in support of the insulin-dependent hypothesis. J Hypertens 1994; 12(8): 965-9.

9. Snorgaard O, Kober L, Carlsen J. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J Intern Med 1997; 242(5): 407-12.

10. Dorella M, Giusto M, Da Tos V, et al. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab 1996; 81(4): 1568- 74.

11. Zimmet P, Collier G. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg. Drugs 1999; 58 (Suppl. 1): 75-82.

12. Mehnert H. Metformin, the revirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes 2001; 109(Suppl. 2): 259-64.


Review

For citations:


Podzolkov V.I., Napalkov D.A., Makolkin V.I. Metformin in metabolic syndrome treatment. Cardiovascular Therapy and Prevention. 2005;4(3, ч.II):61-65. (In Russ.)

Views: 1949


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)